NEWSLETTER NOVEMBER 2020
 |
NEWSLETTER
|
BREAKFAST WEBINAR : DRUG DEVELOPMENT IN ONCOLOGY IN THE ERA OF PRECISION MEDICINE
19th NOVEMBER, 2020 : 08:30am – 09:30am (CET)
Start your day with an insightful presentation with Christophe Le Tourneau, MD, PhD – Senior Medical Oncologist at the Institut Curie as Keynote Speaker and enjoy a delicious treat of luxury Belgian chocolate selections on us!
To attend the session, please register and we’ll send you a voucher following the event, which you can use to order luxury handmade Belgian chocolates.
MORE INFORMATION
REGISTER HERE FOR THE BREAKFAST WEBINAR
ARTICLE : INFECTIOUS DISEASES EPIDEMIOLOGY, QUANTITATIVE METHODOLOGY, AND CLINICAL RESEARCH IN THE MIDST OF THE COVID-19 PANDEMIC: PERSPECTIVE FROM A EUROPEAN COUNTRY Contemporary Clinical Trials 99 (2020) 106189
Marc Buyse, Chief Scientific Officer IDDI, Corresponding author
Starting from historic reflections, the current SARS-CoV-2 induced COVID-19 pandemic is examined from various perspectives, in terms of what it implies for the implementation of non-pharmaceutical interventions, the
modeling and monitoring of the epidemic, the development of early warning systems, the study of mortality, prevalence estimation, diagnostic and serological testing, vaccine development, and ultimately clinical trials.
Emphasis is placed on how the pandemic had led to unprecedented speed in methodological and clinical development, the pitfalls thereof, but also the opportunities that it engenders for national and international collaboration, and how it has simplified and sped up procedures. We also study the impact of the pandemic on clinical trials in other indications. We note that it has placed biostatistics, epidemiology, virology, infectiology, and vaccinology, and related fields in the spotlight in an unprecedented way, implying great opportunities, but also the need to communicate effectively, often amidst controversy.
JOIN IDDI IN SUPPORTING CANCER CHARITY ASSOCIATIONS
We would like to virtually meet and discuss your needs and issues for your upcoming trials and see how we may be able to support your future projects. For every secured and completed meeting we will donate $100 to a Cancer Charity.
You can expect a meeting to take approximately 15 minutes of your time.
There is no requirement of signing a contract with IDDI for a charitable donation, we only ask for a small amount of your time to better understand the issues Sponsors are facing.
Please follow the link to register for a meeting time of your choice. If you would like a meeting and none of the available options work in your schedule, please contact vicky.martin@iddi.signalsuite.com for an alternative time.
Thank you for your support in our giving mission and on behalf of the team at IDDI we wish you Happy Thanksgiving season!
RECORDED WEBINAR : CLINICAL TRIALS FOR, AND DESPITE, COVID-19
In this webinar, the speakers explained the key characteristics of COVID-19 trials, particularly with regard to trial-design features such as trial mechanics (including factorial and multi-stage designs, as well as platform trials), outcome assessment, and other important methodological issues. They presented the impact the pandemic is having on clinical trials in several fields, including oncology and cardiology. And finally they talked about practical issues pertaining to trial design and conduct, including for data capture, data management, statistical analysis, and patient follow-up, all of which affected by the current crisis.
LISTEN TO THE RECORDED WEBINAR
WHITE PAPER : THE IMPACT OF COVID-19 ON RANDOMIZED CLINICAL TRIALS
The COVID-19 pandemic has a major impact on the conduct of most on-going clinical trials, in particular on the treatment of patients and the schedule of their planned protocol visits. General guidance is available from both FDA and EMA on measures to be taken to minimize the impact of COVID-19 on on-going trials; these measures are assumed to have been implemented by Sponsors. IDDI has published an interview with Marc Buyse, Chief Scientific Officer, and Everardo Saad, Oncologist and Medical Director at IDDI on the impact of the pandemic on the statistical analyses of randomized clinical trials
LOOKING FOR A SERVICE PROVIDER FOR YOUR NEXT DEVELOPMENT PROGRAM?
OUR BD TEAM WILL ASSIST YOU REGARDING ANY STATISTICAL OR DATA RELATED SUPPORT
Working great with our colleagues (consultants & Business Operations) to deliver for our clients in these challenging times!
- Erik Falvey, Senior Director, Business Development Europe, erik.falvey@iddi.signalsuite.com
- Vicky Martin, Senior Director, US Business Development, vicky.martin@iddi.signalsuite.com
- Robert Whitaker, Director, Business Development, West Coast USA, robert.whitaker@iddi.signalsuite.com
WE KEEP ON HIRING!
We keep on hiring! Do not miss our career page! Tremendous opportunities in Belgium and in the US. Apply today!
WEBINAR & PRESENTATIONS
In this disruptive time, stay safe and take the opportunity to discover our on-demand recorded webinars.